Trial Profile
A Phase I Study of DNL758 in Healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2020
Price :
$35
*
At a glance
- Drugs Eclitasertib (Primary)
- Indications Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Sanofi
- 07 Aug 2020 Results presented in the Denali Therapeutics Inc media release.
- 07 Aug 2020 Status changed from recruiting to completed, according to a Denali Therapeutics Inc media release.
- 05 Aug 2019 According to a Denali Therapeutics media release, Sanofi has commenced dosing of DNL758 in this trial.